BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 31118572)

  • 1. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
    Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
    Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
    [No Abstract]   [Full Text] [Related]  

  • 2. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
    Luo Y; Ling Y; Guo W; Pang J; Liu W; Fang Y; Wen X; Wei K; Gao X
    J Control Release; 2010 Oct; 147(2):278-88. PubMed ID: 20655966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aptamer-Conjugated Multifunctional Polymeric Nanoparticles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems for Treatment of Castration-Resistant Prostate Cancer.
    Fang Y; Lin S; Yang F; Situ J; Lin S; Luo Y
    Biomed Res Int; 2020; 2020():9186583. PubMed ID: 32420382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
    Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
    Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
    Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS; Yawata T; Honke K
    Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable brush-type copolymer modified with targeting peptide as a nanoscopic platform for targeting drug delivery to treat castration-resistant prostate cancer.
    Liu T; Huang Q
    Int J Pharm; 2016 Sep; 511(2):1002-11. PubMed ID: 27521701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
    Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
    Seo HK; Lee SJ; Kwon WA; Jeong KC
    Prostate; 2020 May; 80(6):453-462. PubMed ID: 32134535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codelivery of miR-4638-5p and Docetaxel Based on Redox-Sensitive Polypeptide Micelles as an Improved Strategy for the Treatment of Castration-Resistant Prostate Cancer.
    Jiang W; Gao Y; Wang Z; Gong C; Hu C; Ding X; Qiang L; Gao S; Ren F
    Mol Pharm; 2019 Jan; 16(1):437-447. PubMed ID: 30452268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.
    Miller DR; Tzeng CC; Farmer T; Keller ET; Caplan S; Chen YS; Chen YL; Lin MF
    Cancer Lett; 2018 Nov; 436():96-108. PubMed ID: 30077739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate.
    Lee MS; Lee JE; Byun E; Kim NW; Lee K; Lee H; Sim SJ; Lee DS; Jeong JH
    J Control Release; 2014 Oct; 192():122-30. PubMed ID: 24995950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer.
    Guo F; Zhang C; Wang F; Zhang W; Shi X; Zhu Y; Fang Z; Yang B; Sun Y
    Cell Death Differ; 2020 Jun; 27(6):1938-1951. PubMed ID: 31857702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of drug efflux inhibitor and chemotherapeutic agent into an inorganic/organic platform for the effective treatment of multidrug resistant breast cancer.
    Dong Y; Liao H; Yu J; Fu H; Zhao D; Gong K; Wang Q; Duan Y
    J Nanobiotechnology; 2019 Dec; 17(1):125. PubMed ID: 31870362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
    Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
    J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
    Shao L; Kahraman N; Yan G; Wang J; Ozpolat B; Ittmann M
    Prostate; 2020 Jan; 80(1):65-73. PubMed ID: 31614005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
    Nagesh PKB; Johnson NR; Boya VKN; Chowdhury P; Othman SF; Khalilzad-Sharghi V; Hafeez BB; Ganju A; Khan S; Behrman SW; Zafar N; Chauhan SC; Jaggi M; Yallapu MM
    Colloids Surf B Biointerfaces; 2016 Aug; 144():8-20. PubMed ID: 27058278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
    Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
    Farokhzad OC; Cheng J; Teply BA; Sherifi I; Jon S; Kantoff PW; Richie JP; Langer R
    Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6315-20. PubMed ID: 16606824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.